Skip to Content

Genentech to Sell Oceanside Clinical Manufacturing Plant

Genentech to Sell Oceanside Clinical Manufacturing Plant [North County Times, Escondido, Calif.]

From North County Times (Escondido, CA) (August 9, 2011)

Aug. 09--OCEANSIDE -- Genentech is selling its Oceanside clinical manufacturing plant, which makes experimental drugs, to Gilead Sciences, company officials said Monday.

Genentech's commercial manufacturing plant, which makes the biotech giant's anti-cancer drugs Avastin and Rituxan, is not included in the sale. Genentech is a unit of Roche, the Swiss pharmaceutical company.

Gilead, which is based in Foster City, declined to disclose the purchase price, spokesman Nathan Kaiser said.

No jobs will be lost as a result of the deal, said Genentech spokeswoman Robin Snyder. Genentech remains committed to its commercial manufacturing operations in Oceanside, Snyder added.

Gilead will retain all 55 people at the clinical plant and related facilities being sold by Genentech.

"There's still about 300 employees that will still be with Genentech at the (commercial) manufacturing plant," Snyder said. "Everything will be staying just the way it is."

The agreement covers what's known as Genentech's Oceanside Clinical Plant, a 70,000-square-foot building at 4049 Avenida de la Plata, and the related facilities. The plant makes a class of biotech drugs called monoclonal antibodies for testing purposes, including for human clinical trials.

Gilead said it initially plans to use the plant to develop and make the experimental drug GS 6624, to be tested in certain cancers and for fibrous tissue diseases, along with another drug now in preclinical testing.

Call staff writer Bradley J. Fikes at 760-739-6641.


To see more of the North County Times or to subscribe to the newspaper, go to

Copyright (c) 2011, North County Times, Escondido, Calif.

Distributed by McClatchy-Tribune Information Services.

For more information about the content services offered by McClatchy-Tribune Information Services (MCT), visit, e-mail, or call 866-280-5210 (outside the United States, call +1 312-222-4544)


Posted: August 2011